Other tumor indications with Hippo-YAP1 pathway alterations have also been reported, including tumors with YAP1 amplifications such as cervical cancer or tumors with NF2 deletions such as renal cell carcinoma and schwannomas meningiomas [34, 41, 45]. Here, NF2 is linked to renal cell carcinoma.